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Abstract
In order to identify good animal models for investigating therapeutic and preventive strategies for
pancreatic cancer, we analyzed pancreatic lesions from several transgenic models and made a series
of novel findings. Female MT-tgfα mice of the MT100 line developed pancreatic proliferation,
acinar-ductal metaplasia, multilocular cystic neoplasms, ductal adenocarcinomas and prominent
fibrosis, while the lesions in males were less severe. MT-tgfα-ES transgenic lines of both sexes
developed slowly progressing lesions that were similar to what was seen in MT100 males. In both
MT100 and MT-tgfα-ES lines, TGFα transgene was expressed mainly in proliferating ductal cells.
Ela-myc transgenic mice with a mixed C57BL/6, SJL and FVB genetic background developed
pancreatic tumors at 2–7 months of age, and half of the tumors were ductal adenocarcinomas,
similar to what was reported originally by Sandgren et al [1]. However, in 20% of the mice, the
tumors metastasized to the liver. MT100/Ela-myc and MT-tgfα-ES/Ela-myc double transgenic mice
developed not only acinar carcinomas and mixed carcinomas as previously reported but also
various ductal-originated lesions, including multilocular cystic neoplasms and ductal
adenocarcinomas. The double transgenic tumors were more malignant and metastasized to the
liver at a higher frequency (33%) compared with the Ela-myc tumors. Sequencing of the coding
region of p16ink4, k-ras and Rb cDNA in small numbers of pancreatic tumors did not identify
mutations. The short latency for tumor development, the variety of tumor morphology and the
liver metastases seen in Ela-myc and MT-tgfα/Ela-myc mice make these animals good models for
investigating new therapeutic and preventive strategies for pancreatic cancer.
Background
Pancreatic cancer is the fourth leading cause of cancer
death in the United States and many other western coun-
tries [2,3]. The five-year survival rate is less than 5% in
most countries [4]. About 75% of human pancreatic can-
cer is ductal adenocarcinomas, whereas acinar cell carci-
nomas and other histological types are less common [5].
An important morphologic feature is that pancreatic duc-
tal adenocarcinomas are frequently associated with prom-
inent fibrosis and multiple cysts [4,6,7]. The cell origin of
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ductal adenocarcinomas is still under debate [8]. Studies
with several experimental animal models suggest that it
may derive from metaplasia (transdifferentiation) of aci-
nar cells or even islet endocrine cells [9,10]. In human
cases, however, hyperplastic and dysplastic epithelial
lesions of the pancreatic ducts have been observed fre-
quently in association with ductal adenocarcinomas [5].
Several studies have suggested a strong association of
severely dysplastic ductal lesions with invasive carcino-
mas [11-14]. More convincingly, a series of pancreatic
intraepithelial neoplasia (PanINs) have been developed
at a think tank sponsored by National Cancer Institute of
the United States as precursors to invasive pancreatic can-
cer [15]. These lines of evidence suggest that ductal cells
may be the origin of ductal adenocarcinomas.
Concomitant expression of epidermal growth factor
receptor (EGFR) with its ligand, such as EGF, transform-
ing growth factor α (TGFα) or amphiregulin has been
associated with decreased patient survival in pancreatic
cancer [16]. In one report, strong TGFα immunoreactivity
was found in 95% of pancreatic tumors, whereas EGF
immunoreactivity was observed in only 12% of the
tumors [17]. Similarly, carcinogen-induced pancreatic
cancer in the hamster and rat expressed only TGFα and
EGFR, but not EGF [18,19]. Data from these human and
animal studies are in line with a generally accepted notion
that TGFα is the preferred trophic factor over other EGFR
ligands for normal ductal cells and cancer cells in the pan-
creas [20-23]. Several lines of transgenic mice have been
established to study the effects of TGFα on pancreatic car-
cinogenesis, of which the tgfα transgenic mouse using
elastase-1 gene promoter (Ela-tgfα) has been studied
extensively [10,24]. The pancreas of these Ela-tgfα mice
develops not only pronounced fibrosis but also obvious
ductal metaplasia of acinar cells because the Ela-promoter
targets the transgene mainly to the acinar cells [24,25].
These acinar-derived ductal cells show progressive prolif-
eration and dysplasia. At one year of age or older, about
25–30% of the animals develop pancreatic tumors, but
the majority of them are acinar cell carcinomas. Several
other tgfα transgenic mouse lines were established using
metallothionin-1 gene promoter (MT-tgfα) [26], but these
mice were much less studied for pancreatic lesions,
although they were frequently used for studies of carcino-
genesis of the mammary gland [27,28] and liver [29].
Overexpression of c-myc mRNA [30] and protein [31] has
been found in about 50% and 43.5% of human pancre-
atic ductal adenocarcinomas, respectively, with about
32.3% of the samples bearing c-myc gene amplification
[31]. Another genetic analysis of 31 human pancreatic
cancer cell lines also showed that 54% of the cell lines
analyzed had c-myc gene amplification [32]. These data
suggest that overexpression or amplification of c-myc may
play an important role in the development or progression
of human pancreatic cancer [33], although there are still
relatively few immunohistochemical data to verify
whether c-Myc protein levels are also increased corre-
spondingly. Animal studies have revealed that pancreastic
cancer induced by chemical carcinogens in the rat also
manifests increased c-myc expression [34,35]. A more
direct and convincing evidence for a critical role of c-myc
in pancreatic carcinogenesis comes from transgenic mice.
Mice carrying c-myc transgene under Ela-promoter
develop pancreatic cancer with 100% penetrance at an
early (2–7 months) age [1]. One-half of the pancreatic
tumors are acinar cell carcinomas, while the remaining
one-half are ductal adenocarcinomas or mixed ductal and
acinar carcinomas [1]. Although this Ela-myc mouse is the
first, and seemingly the only, single-transgene model that
gives rise to frank pancreatic tumors with ductal elements
in the shortest latency period compared with other single-
transgene models [1,36], the pathological characteriza-
tion of the pancreatic lesions from this model has not yet
been described in detail.
Besides the Ela-myc mice, several other transgenic mouse
models have also been generated for study of exocrine
pancreatic cancers [37-42]. However, because currently no
gene promoter/enhancer has been known to be specific
for pancreatic ductal cell [40], all these transgenic mouse
models share a common deficiency: If the transgene is
specifically targeted to the pancreas, such as when driven
by Ela-promoter, it is dominantly expressed in the acinar
cells. Conversely, if the transgene is driven by a promoter
specific for ductal cells, its expression is not pancreas spe-
cific and is usually at low levels. For instance, the MT-pro-
moter targets the transgene to the mammary gland, liver
and pancreas while cytokeratin 19 gene promoter targets
the transgene to the stomach, pancreas and probably
other organs as well [43]; both promoters are much
weaker than the Ela-promoter. Most of the currently exist-
ing transgenic mouse models of pancreatic carcinogenesis
produce only acinar-ductal metaplasia and ductal prolif-
eration, with zero or very low penetrance of developing
frank pancreatic tumors, unless the transgenic mice are
concomitantly deficient in certain tumor suppressor genes
such as Ink4/Arf or p53 [43-49]. For instance, mice with
both Cre-mediated k-ras mutation and Ink4a/Arf gene
deficiency develop metastatic pancreatic ductal adenocar-
cinomas [44]. This animal model requires that a mouse
concomitantly bears at least four transgene alleles, i.e.
Pdx1-Cre, LSL-KrasG12D and homozygous Ink4a/Arflox/lox,
and thus involves extensive animal breeding and genotyp-
ing. Crossing two heterozygous breeders (e.g. Ela-myc
male × Ela-myc female) may increase the frequency of
pups that are transgene carriers. However, pups bred by
this procedure may not be used for testing new therapeu-
tic or preventive methods, because it will produce a mix-
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ture of homozygous and heterozygous pups. It is
technically difficult, if not impossible, to distinguish
homozygosites from heterozygotes for a large number of
pups, and homozygous carriers of transgene may show
different sensitivity to the tested agents compared with
heterozygotes. This concern becomes an issue when the
animals are used for testing therapeutic or preventive
agents, although it may not be an issue for study of carci-
nogenic mechanisms.
Before a gene promoter specific for pancreatic ductal cells
is identified, the best choice may still be to use mice
expressing double oncogenes driven individually by a
pancreas-specific promoter such as Ela-promoter and by a
ductal cell dominant promoter such as MT-promoter. We
used this strategy to study pancreatic carcinogenesis by
crossing MT-tgfα and Ela-myc mice to create MT-tgfα/Ela-
myc mice, considering that the Ela-myc transgene might
also be expressed in the ductal cells, as reflected by the
appearance of various ductal lesions in the Ela-myc pan-
creas, and thus might synergize with the MT-tgfα trans-
gene to induce ductal cell carcinogenesis. This report
summarizes the novel findings from these single and dou-
ble transgenic mice.
Materials and methods
The MT100 line of MT-tgfα transgenic mouse with FVB/N
genetic background [26] was originally purchased from
Jackson Laboratories and maintained at our laboratory in
FVB/N background. In addition, we also received one
male MT-tgfα transgenic mouse [50] and one male Ela-
myc transgenic mouse [1], all in C57BL/6 × SJL back-
ground, from Dr. Eric Sandgren at University of Wiscon-
sin-Madison. In this study the MT-tgfα mouse from Dr.
Eric Sandgren is defined with the initial of his name as
MT-tgfα-ES line, in order to distinguish it from the MT100
line. The FVB mice used for breeding were purchased from
Jackson Laboratories. The breeding procedure for each
single or double transgenic line is described accordingly
in the result section.
Paraffin blocks of 15 cases of human pancreatic ductal
adenocarcinomas were retrieved from the Pathology Tis-
sue Repository of Harper University Hospital at Wayne
State University, under a protocol approved by the human
investigate committee of the University. Criteria for case
selection were histologically proved ductal adenocarcino-
mas and no major treatment before surgical removal of
the tumor. Serial sections in 5 μm thickness were prepared
from each tissue block and were immunohistochemically
stained for TGFα or c-Myc. Sections from mouse pancre-
atic tissue were prepared in the same way. The primary
TGFα antibody was Ab-2 from Oncogene Research Prod-
ucts, San Diego, CA and was used at 1:150 dilution. The c-
Myc antibodies were 9E10 monoclonal (from Sigma, St
Louis, MO) used at 1:150 dilution and C19 polyclonal
(from Santa Cruz Biotech. Inc, Santa Cruz, CA) used at
1:80 dilution. An Avidin-biotin-complex (ABC) method
was used for the staining, as described previously [51,52].
A normal rabbit IgG and a normal mouse IgG were used
to replace the primary antibodies in the mock staining.
Mouse pancreatic tumor tissues that were kept frozen at -
80°C were used for extraction of total cellular RNAs using
the RNeasy kit from Qiagen (Valencia, CA). The extracted
total RNAs were immediately converted into cDNAs using
the TaqMan Reverse Transcription kit from Applied Bio-
systems (Branchburg, NJ). The cDNAs were then used as
PCR templates for the amplification of p16ink4a, k-ras and
Rb. For p16ink4a, the primer pair is p16-L2 (TCACAGT-
GAGGCCGCCGCTGAG)/p16-R592 (AGCTCTGCTCTT-
GGGATTGG) that covers the whole coding sequence. For
k-ras, the primer pair is KRAS-L140 (TGAGGCGCGGCG-
GCTCCG)/KRAS-R878 (CTGACAGTTTGCACGAACA-
GAAG) that also spans the whole coding sequence. For
Rb1, the coding sequence was amplified as three frag-
ments using the following overlapping primer pairs: Rb-
L57 (CGCGCCTCCCTCGGCTGCT)/Rb-R1200 (GAGT-
GTGTGGAGTAACCACG), Rb-L926 (GTGTAATATAGAT-
GAGGTGAA)/Rb-R2071
(AGTGTATTTAGTCGGAGATAT), and Rb-L2011 (CCTC-
CCTTGCCCTGTTTTAC)/Rb-R2919 (CCATGAGCCAG-
GAGTCTGGT). The amplified PCR products were
subsequently subjected to DNA sequencing analysis by
the Sequencing Core Facilities of Wayne State University.
When DNA sequencing revealed nucleotide alterations
that lead to amino acid changes, the above whole proce-
dure was repeated starting from amplifying PCR frag-
ments using the cDNAs. This would rule out the
possibility that the PCR process introduced the alterations
randomly.
Results
Features of pancreatic lesions in MT-tgfα transgenic mice
During our original study of mammary gland tumorigen-
esis involving the MT100 line of MT-tgfα transgenic mice
(FVB/N background), we accidentally found that the
female mice had a much shorter life span than their male
littermates. While males survived well and were still very
healthy at 14 months of age (older mice were not moni-
tored systematically), most females died during 6–8
months of age, showing progressively decreased activity
about one month before death. Because the original
report of this transgenic line described pathologic altera-
tions in the liver and pancreas as well [26], we performed
autopsies of the dead animals and also sacrificed some
transgenic females (in total of 20 animals) at the time
when they were less active or moribund (at the age of 6–8
months). We also sacrificed another 20 transgenic females
at 2–3 months of age as controls of young age and 8 ani-
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mals at different time points during 3–5 months of age.
Female wild type littermates at 2–3 months (5 animals)
and 7 months (4 animals) of age were also included as
normal controls. The liver and pancreas were examined
macroscopically and histologically.
The pancreas of female MT100 mice at 2–3 months
appeared as a solid organ whereas the pancreas of the wild
type littermates appeared as loose tissue. Histological
observation showed progressive death of acinar cells,
while ductal cells proliferated progressively to form
lesions that resembled mouse pancreatic intraductal neo-
plasia (mouse PanINs) described in the literature
[43,45,46], but these lesions are collectively coined as
"ductal proliferation" herein (fig 1A), since it is currently
unclear whether such lesions in the mouse are also cancer
precursors as PanINs in humans. Progressive fibrosis was
associated with the continuing acinar cell death and duc-
tal proliferation (fig 1A). Acinar-ductal metaplasia was
observed, although it seemed to be much less evident than
what was described for Ela-tgfα mice [10,24,25].
In 15 of the 20 MT100 females at age of 6–8 months, the
pancreas became much smaller, roughly about 10% to
20% of the size of the pancreas at age of 2–3 months. At
age of 6–8 months, the pancreas lost about 90% of its
acini and basically consisted of only fibrous tissue and
proliferating ducts, with features of chronic pancreatitis
(fig 1B). Thus, the severe loss of acini is likely the cause of
death, and the female mice might be a good animal
model of chronic pancreatitis. Interestingly, proliferating
ducts also appeared in islets (arrow in fig 1C), resembling
the ductuloinsular body in humans. This trait indicates
that in this transgenic line, either the islets might contain
certain stem cells with multiple potential that could pro-
liferate to form ductal lesions or some endocrine cells
might be capable of undergoing ductal metaplasia and
forming ductal lesions, as suggested by certain animal
models [8,9]. Areas of cell death (likely necrosis) were
also observed frequently in islets (fig 1D). In the other five
older females the pancreas showed the opposite changes
macroscopically, i.e. enlargement, due to the fact that pro-
liferating ducts formed multiple cysts; some cysts were
filled with liquid and developed multilocular cystic neo-
plasms (fig 1E) that were as large as 1.5 cm3. Areas of well
differentiated ductal adenocarcinomas (fig 1F) were
observed in two of the 20 older mice studied.
We also sacrificed 30 and 20 male MT100 mice at ages of
12–14 months and 2–3 months, respectively, and an
additional 15 male transgenic mice in between ages. We
also sacrificed five 3-month-old and five 13-month-old
male wild type littermates as normal controls. Male
MT100 mice at age of 2–3 months started to show death
of acinar cells, ductal metaplasia of acinar cells, prolifera-
tion of ductal cells, and formation of fibrosis, but these
alterations were not as obvious as seen in the age-matched
females. Opposite to what was seen in female MT100
mice, the pancreas of males became larger with increased
age and body weight. Thus, the pancreas of the males at
age of 12–14 months was much larger than the pancreas
of males at 2–3 months of age and showed pronounced
fibrosis and ductal proliferation and metaplasia, although
these lesions were still much less severe compared with
the pancreas of females at 6–8 months of age. No multi-
locular cystic neoplasms and ductal adenocarcinomas
were observed in male mice.
We also crossed a male MT-tgfα-ES line (C57BL/6 × SJL
background) with a female FVB mouse. The F1 transgene
carriers were crossed with F1 wild type mice to produce F2
animals and some F2 mice were crossed together to pro-
duce F3 mice. Both F1 and F2 MT-tgfα-ES carriers did not
show obvious sex difference in survival since all 30 ani-
mals of both sexes survived well over 14 months of age
(older mice were not monitored systematically). In addi-
tion, we also sacrificed another 37 F2 and F3 mice (18
males and 19 females) at different time points during 2–
10 months of age. Histologically, the pancreas of these
mice manifested ductal metaplasia of acinar cells, prolif-
eration of ductal cells, formation of small cysts, and fibro-
sis, similar to what was reported originally by Sandgren et
al. for the MT-tgfα-ES line with C57BL/6 × SJL genetic
background [50]. However, these alterations not only
occurred much later (after 4 months of age) but also pro-
gressed much slower compared with age- and sex-
matched MT100 mice. Female predilection could be dis-
cerned after 9 months of age (fig 1Gvs 1H), but even at 14
months of age the sex difference was still not as pro-
nounced as in MT100 mice at age of 6–8 months, because
the lesions in female MT-tgfα-ES mice were much less
severe. No multilocular cystic neoplasm or ductal adeno-
carcinoma was discerned in MT-tgfα-ES mice, but mice
older than 14 months were not examined. Unlike what
was reported by Sandgren et al. [53], we did not observe
any macroscopic liver tumor in our MT-tgfα-ES mice with
mixed C57BL/6, SJL and FVB background.
Immunohistochemistry showed a preferential staining of
TGFα in ductal cells in both MT100 and MT-tgfα-ES lines
(fig. 1I). The staining was strong in most proliferating duc-
tal cells but was weak or undetectable in acinar cells. Even
within the same acinar-ductal loop (arrow in fig. 1I), the
ductal cells showed intense positive staining while the aci-
nar cells were negative.
Features of pancreatic lesions from Ela-myc transgenic 
mice
We crossed one male Ela-myc mouse (C57BL/6 × SJL back-
ground) with a female FVB mouse and then crossed F1
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Histological alterations of the pancreas from MT-tgfα transgenic miceFigure 1
Histological alterations of the pancreas from MT-tgfα transgenic mice. A: a representative area of the pancreas from a 3-
month-old female MT100 mouse, showing formation of fibrosis, proliferating ductal lesions (arrow) that manifest intraductal 
mucinous changes. B: a pancreas from an 8-month-old female MT100 mouse showing prominent fibrosis and severe loss of 
acini, with features of chronic pancreatitis. C: hyperplastic ducts (arrows) in an islet resembling ductuloinsular body in humans, 
from a 6-month-old female MT100 mouse. D: Large necrotic areas seen in an islet, from a 6-month-old female MT100 mouse. 
E: Low magnification of multiocular cystic neoplasms from an 8-month-old female MT100 mouse. F: Well differentiated ductal 
adenocarcinomas with chronic pancreatitis, from a 6-month-old female MT100 mouse. G: A representative area of the pan-
creas from a 9-month-old female MT-tgfα-ES mouse, showing early formation of small cysts and fibrosis. H: A representative 
area of the pancreas from a 9-month-old male MT-tgfα-ES mouse, which was a littermate of the female shown in G. I: Immuno-
histochemical staining of TGFα in a 3-month-old female MT100 mouse, noting that within the same acinar-ductal loop, only the 
ductal cells, but not the acinar cells, are positive.
1A 1B 1C
1D 1E 1F
1G 1H 1I
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pups together to produce F2 transgene carriers. Some F2
animals were also crossed together to produce F3 mice.
Sixty F1, F2 and F3 Ela-myc mice of both sexes showed
enlarged abdomen, a sign of bearing large pancreatic
tumor, at ages between 2–7 months as originally reported
by Sandrgen et al. [1]. The animals were sacrificed at this
period of age when the tumor burden reached the ethical
limit or the animals became weak and showed decreased
activity. Most tumors weighed 3–4 grams (fig 2A). Perito-
neal metastatic tumor seeds were found in 41 (68%) ani-
mals. Although Sandgren et al. did not mention liver
metastasis in their original report of this transgenic line
with C57BL/6 × SJL background [1], in 12 (20%) mice we
observed macroscopic liver metastasis (fig 2B), which was
confirmed histologically to be of pancreatic origin (fig
2C). All the peritoneal and liver metastases occurred at
advanced stage, i.e. 4–7 months of age. Microscopic
metastasis in the liver was not examined systematically
but likely existed in some of the animals that did not show
macroscopic metastasis. No macroscopic metastasis in the
lung or other organs was found.
At the time of sacrifice, the tumor from each animal man-
ifested multiple nodules, presumably a reflection of mul-
tiple original tumors (fig 2A). Some tumor nodules were
fish-meat-like white, a typical sign of solid cancer in
humans, while some other tumor nodules were a deep red
color due to hemorrhage within the tumor (fig 1A). His-
tologically, about one-half of the tumors were pure acinar
cell carcinomas (fig 2D and 2E), while the other one-half
were mixed ductal and acinar carcinomas that could be
manifested either as mixed cell carcinomas (fig 2F) or as
patches of ductal adenocarcinomas (fig 2G and 2H) and
other patches of acinar cell carcinomas, similar to what
was described in Sandgren et al's original report [1]. While
acinar tumors could be either white or red in color, all
ductal adenocarcinomas were white in color. Interest-
ingly, some acinar tumors also appeared in endocrine
islets (arrow in fig 2I). Acinar cell carcinomas manifested
many apoptotic cells (fig 2E) and large areas of necrosis.
The apoptotic cells were not randomly distributed but,
instead, were usually organized in clusters that were
coined "dead cell islands" in the description of apoptotic
cells in the mammary tumors of MMTV-c-myc transgenic
mice [28]. Acinar cell tumors contained little stroma (fig
2E), but invasive growth into the adjacent stroma was
observed at advanced stages. Unlike acinar cell tumors,
ductal tumor cells were usually disseminated in the dense
stromal tissue, (fig 2F and 2G), similar to desmoplasia
observed in human pancreatic ductal adenocarcinomas.
Some ductal areas had some acidophilic cells reminiscent
of oncocytic changes. Apoptotic cells and large necrotic
areas were much less frequently observed in ductal
tumors, compared with acinar tumors.
We also sacrificed 10 mice at 2 months of age that had not
yet shown enlarged abdomen and found that 4 of the ani-
mals already had small cancer nodules (1–6 mm in diam-
eter). Two of these 4 mice had only one tumor nodule in
the head of the pancreas while the other two mice had two
tumor nodules, one at the head and the other at the tail of
the pancreas. It is likely that the head of pancreas is more
susceptible for the tumor development, although the c-
myc transgene can also induce tumors in other parts of the
pancreas. This phenomenon was not mentioned in the
original report by Sandgren et al [1] and thus whether it
also occurred in the original Ela-myc mice with C57BL/6 ×
SJL background is unclear.
Features of pancreatic lesions in MT-tgfα/Ela-myc double 
transgenic mice
We crossed Ela-myc mice with MT100 mice bred during
the above-described procedure and obtained 21 double
transgenic animals with mixed C57BL/6, SJL and FVB
background. The majority (16; 76%) of these mice were
sacrificed at 3–5 months of age, but the others were sacri-
ficed as early as 2 months or as late as 6 months of age,
because they became weak or the tumor burden reached
the ethical limit. It seemed that the double transgenic
tumors developed earlier or grew faster than the Ela-myc
tumors, but the difference was not statistically significant
in this small number of tumors.
Macroscopically, the tumors looked similar to those from
Ela-myc mice. However, usually part of the white color
tumors, but not the red color ones, manifested cystic fea-
tures. Although Sandgen et al. did not observe ductal ele-
ments in their Ela-tgfα/Ela-myc and MT-100/Ela-myc
double transgenic mice [53], we found that the pancreas
of our double transgenic mice manifested a combination
of lesions seen individually in the MT-tgfα mice and the
Ela-myc mice, including proliferating ducts (fig 3A), mul-
tilocular cystic neoplasms (fig 3A and 3B), acinar cell car-
cinomas (fig 3C), various ductal adenocarcinomas (fig
3D, 3E and 3F) and mixed acinar and ductal carcinomas
(fig 3G). Dysplastic ductal lesions were also observed and
usually mixed with acinar tumor cells (fig 3H). The ductal
lesions, such as multilocular cystic neoplasms and ductal
adenocarcinomas, seemed to be more prominent in the
female mice than in males. Some tumor cells manifested
certain squamous differentiation (fig 3I). Fibrosis was also
observed (fig 3B) but was much less severe compared with
age- and sex-matched mice of MT100 line. Similar to what
was seen in Ela-myc mice, one-half of the tumors were aci-
nar cell carcinomas and another one-half were ductal
tumors or mixed ductal and acinar cell tumors. In general,
double transgenic tumors of either acinar or ductal cell
origin were more malignant, i.e. less differentiated, than
the tumors from Ela-myc mice, as previously reported by
Sandrgen et al. [53]. Acinar cell tumors contained little
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Alterations of the pancreas from Ela-myc transgenic miceFigure 2
Alterations of the pancreas from Ela-myc transgenic mice. A: a photo showing a huge nodular pancreatic tumor (arrows). Note 
that one tumor nodule is in red color while other tumor nodules are in white color. B: liver metastases (arrows) of a pancre-
atic tumor. C: histological examination confirming that the liver tumors are pancreatic origin (acinar cell carcinoma). D: a typi-
cal histology of acinar cell carcinoma that shows red color macroscopically. E: a typical histology of the acinar cell carcinoma 
that shows white color macroscopically. Note that there are many apoptotic cells that are organized in clusters, coined as 
"death cell islands" (arrows). F: a typical area of mixed acinar and ductal adenocarcinomas. G: a pancreatic ductal adenocarci-
noma. Note that the tumor contains abundant stroma. H: another typical ductal adenocarcinoma. I: an acinar cell carcinoma 
within an islet (arrow).
2A 2B 2C
2D 2E 2F
2G 2H 2I
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Histological alterations of the pancreas from MT-tgfα/Ela-myc double transgenic miceFigure 3
Histological alterations of the pancreas from MT-tgfα/Ela-myc double transgenic mice. A: multilocular cystic neoplasms mixed 
with acinar tumor cells (arrows). B: a large benign multilocular cystic neoplasm. C: a typical acinar cell carcinoma. D: one type 
of ductal adenocarcinoma. E: another type of ductal adenocarinoma. F: a much less differentiated ductal adenocarcinoma with 
feature of desmoplasia. G: a mixed acinar and ductal adenocarcinoma. H: an area showing feature of mouse PanIN3 or ductal 
adenocarcinomas (dark arrows) with acinar tumor cells (yellow arrows) in the surrounding. I: a tumor area showing squamous 
differentiation.
3A 3B 3C
3D 3E 3F
3G 3H 3I
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stroma, similar to Ela-myc acinar tumors, whereas ductal
tumors were abundant with stromal tissue, somewhat
resembling pancreatic ductal adenocarcinomas in
humans. Necrotic areas and apoptotic cells appeared in
both acinar tumors and ductal tumors but were more fre-
quent in acinar tumors.
We observed macroscopic liver metastasis in 7 of 21
(33%) double transgenic animals. This rate is significantly
(χ2 test, p < 0.05) higher than the metastatic rate (20%) in
Ela-myc mice. Microscopic metastasis was not systemati-
cally examined but likely existed in some of those animals
that did not show macroscopic metastasis. Peritoneal
Immunohistochemical staining for c-Myc and TGFα in human pancreatic ductal adenocarcinomasFigure 4
Immunohistochemical staining for c-Myc and TGFα in human pancreatic ductal adenocarcinomas. 4A, 4B and 4C: c-Myc stain-
ing showing that most tumor cells manifest positive nuclear staining. 4D and 4E: TGFα staining showing most tumor cells are 
positive for TGFα. Note that the staining is mainly localized in the cytoplasm of most tumor cells, but it is also localized in the 
nucleus (arrows) of some tumor cells. 4F: a "normal" area of pancreatic tissue adjacent to cancer, showing that ductal cells 
(arrows), but not acinar cells, are positive for TGFα.
TGFD TGFD TGFD
Myc Myc Myc4A 4B 4C
4D 4E 4F
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tumor seeds were also frequently found, as seen in Ela-myc
mice. No macroscopic metastasis in the lung or other
organs was found.
We also crossed some Ela-myc mice with the MT-tgfα-ES
line and got 9 double transgenic pups. The pancreatic
lesions of these mice were in general similar to the
MT100/Ela-myc mice described above, but less multilocu-
lar cystic neoplasms were observed compared with
MT100/Ela-myc mice. Two of these mice appeared to have
macroscopic liver metastasis.
Expression of c-Myc and TGFα in human ducal pancreatic 
adenocarcinomas
So far there are still relatively few publications on immu-
nohistochemical data of c-Myc in human pancreatic can-
cer, and some of the early studies might be limited due to
the lack of optimal c-Myc antibodies for immunohisto-
chemistry on paraffin-embedded tissue sections. There-
fore, we conducted immunohistochemical staining on a
small number of human samples of ductal adenocarci-
noma to confirm the relevance of c-Myc oncoprotein to
human pancreatic cancer. Immunohistochemical staining
was carried out with one monoclonal and one polyclonal
antibody. The two antibodies gave rise to very similar
staining, and only those tissue areas that showed staining
with both antibodies were considered positive. We found
that 13 of 15 cases showed moderate to strong staining in
about 20–70% of the tumor cells. The staining was mainly
localized to the nucleus (fig 4A, 4B and 4C), although
many tumor cells also showed weak cytoplasmic staining.
Fibroblasts in the stroma were negative. "Normal" pancre-
Sequencing data of k-ras and Rb cDNAFig re 5
Sequencing data of k-ras and Rb cDNA. Panel A, chromatogram showing nucleotide change of k-ras; panel B and C, chromato-
grams showing nucleotide changes of Rb; panel D, Comparison of part of the amino acid sequences of the Rb proteins among 
mouse, rat and human. The single-letter amino acid sequence of the mouse, rat and human Rb protein is represented. A verti-
cal bar represents amino acid identity between any two of the three species.
Mouse 819  TPRSRILVSIGESFGTSEKFQKINQMVCNSDRVLKRSAEGGNPPKPLKNVRFDIEGADEA  878
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
IIIIIIIIIIIIII  IIIIIII
Rat861  TPRSRILVSIGESFGTSEKFQKINQMVCNSDRVLKRSAEGGNPPKPLKK LRFDIEGSDEA  920
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
Human 826  TPRSRILVSIGESFGTSEKFQKINQMVCNSDRVLKRSAEGSNPPKPLKK LRFDIEGSDEA   885
A
B
C
D
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atic tissue and pancreatitis tissue adjacent to the tumors
were also negative. The mock staining using normal rabbit
IgG to replace c-Myc antibodies did no give rise to any
staining, confirming the signal specificity of the antibod-
ies.
The staining for TGFα revealed that TGFα was also highly
expressed in the 13 cases that were positive for the c-Myc
but negative in the 2 cases that failed to show c-Myc stain-
ing. It is likely that these two cases might not have been
properly fixed or might have had other unknown defects.
In these 13 cases, about 30–70% of the tumor cells were
moderately to strongly positive for TGFα. In most cancer
cells, the staining was localized to the cytoplasm (fig. 4D
and 4E), but nuclear staining was also observed in some
cancer cells (arrows in fig. 1E), suggesting that TGFα
might have transcriptional activity, like EGF [54]. In the
adjacent "normal" or pancreatitis tissues that might have
certain proliferating potential, many ductal cells, but not
acinar cells, were also positive for TGFα (arrows in fig 4F).
These results not only dovetail with the thought that
TGFα is important for the growth and development of the
pancreas but also indicate that the positivity of TGFα may
be indicative of ductal cell origin of the cancer. Fibroblasts
in the tumor stroma were negative.
Sequencing of p16ink4a, k-ras and Rb cDNA
Eleven (8 Ela-myc and 3 MT-tgfα/Ela-myc) tumors were
sequenced for the entire coding region of p16ink4a cDNA.
None of them showed any nucleotide alteration when
compared with the NCBI gene bank sequence (acces-
sion#: NM_009877). Twelve (9 Ela-myc and 3 MT-tgfα/
Ela-myc) tumors were sequenced for the entire coding
region of the k-ras cDNA. Eleven of them did not show
any nucleotide alterations when compared with the NCBI
gene bank sequence (accession#: NM_021284), while one
sample had a single nucleotide change (TAC→TAT) at
codon 32, which does not change amino acid sequence
(fig. 1, panel A) and thus is considered a polymorphism.
Five Ela-myc tumors were sequenced for the coding region
of the Rb gene. All of them showed one nucleotide differ-
ence at codons 836 (GAG→GAA), 867 (AAC→AAG) and
868 (GTG→CTG) (panel B and C of fig 1), when com-
pared with the NCBI gene bank sequences (accession#
NM_009029 and M26391). Whereas the nucleotide dif-
ference at codon 836 did not change the amino acid
sequence, the difference at codons 867 and 868 caused
changes of two consecutive amino acids, i.e. an asparagine
(N) was changed to a lysine (K) at codon 867 and a valine
(V) to a leucine (L) at codon 868. Comparison of the Rb
protein sequences among mouse, rat and human revealed
that the domain that harbors the mouse codons 867 and
868 were highly conserved among these three species. Rb
cDNA in both rat and human has the lysine (K) and leu-
cine (L) at the positions corresponding to codons 867 and
868 in the mouse Rb cDNA, as shown in panel D of Figure
1. Moreover, the mouse genome sequence (access # NC-
000080) deposited more recently in the NCBI data base
also showed that the mouse Rb genomic DNA sequence at
these three codons was the same as our sequencing data.
We thus considered that the mouse Rb cDNA sequences at
NCBI gene bank might be wrong. To further clarify this
issue, we sequenced the cDNA of a cell line derived from
one Ela-myc pancreatic tumor (Ela-myc-1) that was
described in our recent publication [55], as well as the
NMuMG cells, a normal mouse mammary epithelial cell
line purchased from ATCC. We also sequenced cDNA
from a normal mouse kidney tissue. The sequencing data
from all these cell lines and kidney tissue showed the
same nucleotide sequence as Ela-myc tumor tissue. There-
fore, it is likely that the Rb gene in Ela-myc tumors was not
mutated but, instead, the mouse Rb cDNA sequences at
the NCBI gene bank (accession# NM_009029 and
M26391) may have mistakes at these three nucleotides.
Discussion
Although the MT100 and MT-tgfα-ES lines of MT-tgfα
mice as well as the Ela-myc mice have been established for
over a decade, so far there are only several published stud-
ies using these transgenic mice to address pancreatic car-
cinogenesis, and detailed characterization of the
pancreatic lesions from these mice is still lacking. During
a study of mammary carcinogenesis of MT100 mice, we
accidentally found, for the first time, the obvious sex dif-
ferences in the pancreatic lesions of this transgenic line.
Bardeesy et al. observed multiple cystic lesions with simi-
larly low penetrance in MT42, another MT-tgfα transgenic
line, but only in the mice that were concomitantly defi-
cient in one allele of Ink4a and/or p53 gene, not in the
MT42 mice with wild type of any of these two genes [56].
The reason for this discrepancy could be due to the facts
that their mice were from another transgenic line and had
different genetic background, and that the gender of the
mice (25 animals) in their study was not described. It is
known that in humans various types of cystic neoplasms
of the pancreas have malignant potential and show
female predominance [57-60]. It deserves further studies
whether our observation of female predilection of multi-
locular cystic neoplasms in the MT100 mice is etiologi-
cally or mechanistically relevant to such benign
neoplasms in the human pancreas, although the multiloc-
ular cystic neoplasms in the mice resemble, histologically,
the cystic lesions observed in the human pancreas, as have
shown by Bardeesy et al. [56]. In our MT100 mice, these
well-demarcated multiolcular cystic lesions had loose
mesenchyme in the septae, closely resembling ovarian
like stroma of human mucinous cystic neoplasm. Moreo-
ver, there were luteal type cells, further supporting this
hypothesis.
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In both MT100 and MT-tgfα-ES lines, TGFα is found
expressed preferentially in the proliferating ductal lesions,
not in the acinar cells or stromal tissue. This expression
pattern is different from the dominant expression of the
transgenes in the acinar cells of Ela-promoter driven trans-
genic mice. This difference in the expression patterns may
partly explain why the transdifferentiation from acinar
cells to ductal cells was not as evident in our MT100 mice
as described by Schmid et al. for the Ela-tgfα mice
[10,24,25]. Because Ela-tgfα and MT-tgfα preferentially
target to different cell types, the underlying mechanisms
for the formation of fibrosis and the death of acinar cells
in these two different transgenic lines may be mechanisti-
cally different. It is possible that in MT100 mice, constitu-
tive overexpression of the tgfα transgene in the ductal cells
causes, perceivably via epithelial-stromal interaction, con-
tinuous growth of connective tissue to form fibrosis,
which in turn leads to continuous death of acinar cells. It
needs to be further explored why and how ductal-derived
TGFα induces progressive death of acinar cells and growth
of stroma in MT100 mice. On the other hand, MT-tgfα/
Ela-myc double transgenic mice showed much less pro-
nounced fibrosis in the pancreas, compared with MT-tgfα
mice. An explanation is that overexpressed c-Myc sup-
presses TGFα induced formation of fibrosis, although
TGFα facilitates c-Myc induced pancreatic carcinogenesis
by inducing more malignant phenotypes of the tumors. A
similarly less evident fibrosis was also observed in the
mammary tumors from MT-tgfα/MMTV-myc double
transgenic mice than in the fibrous mammary gland of
MT-tgfα mice [28]. The molecular mechanism behind this
phenomenon is currently unknown.
The finding of liver metastasis of the pancreatic tumors in
Ela-myc mice is a surprise, since it was not described by
Sandgren et al. in their original report of this transgenic
line [1]. The reason for this different observation is
unclear. We intend to consider that the mixed C57BL/6,
SJL and FVB genetic background of our animals renders
the pancreatic tumor a higher metastatic ability. However,
the changed genetic background does not seem to alter
the latency for the tumor development, since our animals
develop pancreatic tumors at the same age as reported by
Sandgren et al. [1]. Despite the unexplained discrepancy,
this finding makes the Ela-myc mouse the first single-
transgene model that yields a high metastatic rate. Endog-
enous expression of mutant k-ras in a transgenic model
has been shown to cause ductal proliferation that occa-
sionally progresses to frank tumors with invasive and met-
astatic potential [46]. Another two transgenic mouse lines
using Ela-promoter to target k-ras mutant or Ela-SV49TAg
to the pancreas develop only mouse PanINs [1,43,45,47]
but not frank tumors of exocrine origin. Development of
frank, metastatic tumors requires combination of expres-
sion of k-ras mutant or Ela-SV49TAg with the deficiency of
the Ink4a/Arf gene [44,46,47]. The k-ras mutant/Ink4a-/-
model [44] gives rise to metastatic ductal adenocarcino-
mas and is thus very useful for mechanistic research of
pancreatic carcinogenesis. However, it requires that a
mouse concomitantly bears four transgene alleles, i.e.
Pdx1-Cre, LSL-KrasG12D and homozygous Ink4a/Arflox/lox.
This model, and another one that involves expression of
k-ras mutant and p53 knockout, requires extensive animal
breeding and genotyping, which greatly limits its use for
the purpose of studying new therapeutic or preventive
methods or agents. Therefore, several characteristics of
Ela-myc mouse, i.e. high frequency of ductal adenocarci-
nomas, high metastatic rate, short latency of carcinogene-
sis, and the easiness of breeding and genotyping make it a
very useful animal model for studying pancreatic carcino-
genesis and testing new therapeutic and preventive meth-
ods or agents.
Although Sandgren et al. did not observe ductal elements
in the pancreatic tumors from their Ela-tgfα/Ela-myc or
MT-tgfα/Ela-myc double transgenic mice [53], we found
that proliferating ductal lesions, multilocular cystic neo-
plasms and ductal adenocarcinomas occurred frequently
in the pancreas of our MT-tgfα/Ela-myc mice. Sandgren et
al. considered that the reason for the lack of ductal ele-
ments could be due to the earlier development of more
malignant tumors with reduced life span of these animals
[53]. Reduction in the life span seems to be less evident in
our double transgenic animals since it does not reach the
statistically significant level when compared with the Ela-
myc mice. In addition, we also found that MT-tgfα/Ela-myc
double transgenic tumors metastasize to the liver at a
higher frequency than the Ela-myc pancreatic tumors,
although the liver metastasis of the double transgenic
tumors was, again, not observed in the study of Sandgren
et al. [53]. Differences in the genetic background of the
mice may be one of the explanations for the different
observations. This seemingly banal caveat is supported by
the facts that Sandgren et al. found primary liver tumors in
their MT-tgfα mice at a high frequency (16 of 27 animals)
and in their wild type mice at a low frequency (1 of 20 ani-
mals) during 26–104 weeks of age [53], whereas we did
not find any primary liver tumors in any of our MT-tgfα
mice or their wild type littermates up to 12 months of age.
k-ras, Rb and p16ink4a are the genes showing mutations or
inactivation at high frequencies in human pancreatic can-
cer. Surprisingly, although the Ela-myc and MT-tgfα/Ela-
myc tumors were highly malignant and have metastatic
ability, they did not show mutations in these genes, at
least not at high frequencies. Schaeffer et al had also
sequenced the k-ras in Ela-myc tumors and did not find
mutation [61].
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In summary, this study documents a series of novel find-
ings in several single and double transgenic mouse mod-
els established previously by other investigators. Female,
but not male, MT-tgfα (MT100 line) mice developed mul-
tilocular cystic neoplasms and ductal adenocarcinomas at
low penetrance. Ela-myc mice with mixed genetic back-
ground develop pancreatic cancers that metastasize to the
liver. MT-tgfα/Ela-myc dual transgenic mice develop a vari-
ety of pancreatic lesions including multilocular cystic neo-
plasms and ductal adenocarcinomas that are not reported
previously. Moreover, the double transgenic tumors
metastasize to the liver at a higher frequency than the Ela-
myc pancreatic tumors. The early formation and the vari-
ety of the tumor morphology, as well as the potent meta-
static ability seen in the Ela-myc and MT-tgfα/Ela-myc
transgenic mice, make them good animal models for test-
ing new therapeutic and preventive regimens or agents for
the management of pancreatic cancer.
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